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Abstract
Epigenetic changes frequently occur during tumorigenesis and DNA hypermethylation may account for the inactivation of
tumor suppressor genes in cancer cells. Studies in Multiple Myeloma (MM) have shown variable DNA methylation patterns
with focal hypermethylation changes in clinically aggressive subtypes. We studied global methylation patterns in patients
with relapsed/refractory MM and found that the majority of methylation peaks were located in the intronic and intragenic
regions in MM samples. Therefore, we investigated the effect of methylation on miRNA regulation in MM. To date, the
mechanism by which global miRNA suppression occurs in MM has not been fully described. In this study, we report
hypermethylation of miRNAs in MM and perform confirmation in MM cell lines using bisulfite sequencing and methylation-
specific PCR (MSP) in the presence or absence of the DNA demethylating agent 5-aza-29-deoxycytidine. We further
characterized the hypermethylation-dependent inhibition of miR-152, -10b-5p and -34c-3p which was shown to exert a
putative tumor suppressive role in MM. These findings were corroborated by the demonstration that the same miRNAs were
down-regulated in MM patients compared to healthy individuals, alongside enrichment of miR-152-, -10b-5p, and miR-34c-
3p-predicted targets, as shown at the mRNA level in primary MM cells. Demethylation or gain of function studies of these
specific miRNAs led to induction of apoptosis and inhibition of proliferation as well as down-regulation of putative
oncogene targets of these miRNAs such as DNMT1, E2F3, BTRC and MYCBP. These findings provide the rationale for
epigenetic therapeutic approaches in subgroups of MM.
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Introduction
Gene promoter DNA hypermethylation is one of the major
epigenetic mechanisms responsible for silencing of tumor suppres-
sor genes in a variety of malignancies [1], suggesting DNA
methylation as a target for novel therapeutic agents. DNA
methylation occurs at cytosine residues mainly in CpG islands,
which represent specific genomic regions containing a high
frequency of CpG sites [2]. Most CpG islands are located in the
proximal promoter regions of genes and are usually methylated in
tumor cells, mediating the inactivation of genes [3]. Recent studies
have also highlighted the importance of miRNAs in supporting
tumorigenesis [4–11].
MicroRNAs (miRNAs) are small non-coding RNAs of 19–25
nucleotides in length. In animals, miRNAs interact with specific
target mRNAs, via complementary binding to sequences within
the 39 UTR, where they induce mRNA degradation or
translational inhibition [5,9]. In the vast majority of tumors,
miRNAs are down-regulated in clonal cells, thus suggesting their
ability to act as tumor suppressors [6,7,10,11]. However, the
mechanisms that control the expression of miRNAs are largely
unknown. Prior studies have shown that miRNAs can be regulated
by aberrant methylation of CpG islands encompassing miRNAs or
adjacent to miRNAs [4]. For example, methylation-dependent
silencing of the tumor suppressor-miR-127 and -124a has been
identified in different tumor types [8,12].
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110973Aberrant promoter methylation has been described in multiple
myeloma (MM) [13–17]. Specifically, p16 methylation represents
one of the epigenetic aberrations that contribute to MM disease
progression [18]. In addition, methylation-dependent silencing of
multiple soluble Wnt antagonists, such as WIF1, DKK3, and APC
has been reported in MM, thus explaining at least in part, the
constitutive activation of Wnt signaling in clonal MM cells [19].
Moreover, epigenetic inactivation of the tumor suppressive
miRmiR-194-2-192 cluster and miR-203 is implicated in the
pathogenesis of MM [20,21]. However, these studies highlight the
methylation status of single genes or miRNAs, with highly variable
prevalence of promoter hypermethylation within the same gene.
Herein, we used chromatin immunoprecipitation (ChIP) and
array-based hybridization (ChIP-chip) to examine enrichment
patterns of CpG islands in primary CD138
+ bone marrow (BM)
cells isolated from both MM patients and healthy donors (HD) and
identified hypermethylation adjacent to miR-152, -10b-5p and
miR-34c-3p. Moreover, by treating MM cells with a DNA
demethylating agent 5-aza-29-deoxycytidine (5-aza-CdR) we
identified up-regulated miRNAs. Further validation experiments
showed that miR-152, miR-10b-5p and miR-34c-3p were highly
methylated, which may explain, at least in part, their low
expression levels in MM. Finally, we showed that these three
miRNAs act as putative tumor suppressor miRNAs by modulating
several oncogenes in MM.
Methods
Cell lines and Tissue samples
The human MM cell lines MM.1S, RPMI 8226, OPM2, U266,
IM9 and H929 were obtained from the American Type Culture
Collection and grown in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS), 2 mM/ml L-glutamine, 100 U/mL penicil-
lin, 100 mg/mL streptomycin (Invitrogen) as described previously
[22]. Cells were treated with 5 mM of 5-aza-CdR (Sigma Aldrich)
for 4 days, replacing the drug and medium every 24 hours [23].
Primary bone marrow stromal cells (BMSCs) were obtained from
the bone marrow of patients with MM as described previously [22]
and cultured in DMEM plus 20% FBS. Primary plasma cells were
obtained from BM samples from patients with relapsed-refractory
MM (N=8). 5 males and 3 females were studied; median age
60 years old (range 48–75 years old). All the MM cases evaluated
in these studies were patients with relapsed-refractory disease, who
were off-therapy when bone marrow aspirates were collected.
Previous therapies included either lenalidomide- or bortezomib-
based regimens. Plasma cells were also collected from HD (N=6).
HD samples were then collected as 2 pooled control samples.
Plasma cells were obtained using CD138
+ microbead selection
(Miltenyi Biotec, Auburn, CA) as previously described [22].
Approval for these studies was obtained from the Dana-Farber
Cancer Institute Institutional Review Board. Informed consent
was obtained from all patients and healthy volunteers in
accordance with the Declaration of Helsinki protocol.
ChIP-chip-based DNA methylation analysis
ChIP and ChIP-chip was performed according to described
protocols [24] with some modifications. CD138
+ plasma cells were
obtained from MM patient bone marrow. 5 males and 3 females
were studied; median age 60 years old (range 48–75 years old). All
the MM cases evaluated in these studies were patients with
relapsed-refractory disease, who were off-therapy when bone
marrow aspirates were collected (i.e., at the time of progression).
Previous therapies included either lenalidomide- or bortezomib-
based regimens. CD138+ plasma cells were collected from 6
healthy donors and used for ChIP as 2 pooled controls. Cells were
allowed to crosslink with 1% formaldehyde. After washing with
ice-cold PBS, the cell suspension, in SDS lysis buffer, was
disrupted by sonication on ice to gain genomic DNA fragments
between 200 and 1000 bp. ChIP was performed with anti-59-
methyl-cytosine. Immunoprecipitated complexes were sequentially
eluted and cross-link reversed. DNA fragments were purified using
a PCR purification kit (Qiagen). The ChIPed DNA was amplified
and hybridized to the Affymetrix GeneChip Human Tiling 2.0R
Array Set as previously described [25]. DNA without immuno-
precipitation was used as the input control. Microarray data was
normalized by quantile normalization using Bioconductor [26].
The normalized data was then analyzed using the model-based
analysis of tiling (MAT) array algorithm to identify genomic
regions with the highest mean histone methylation scores [27].
Default parameters were used for each algorithm to find ChIP
regions from all samples. The MAT library and mapping files were
annotated with the nearest reference gene (1 kb distance) using the
refseq annotation file based on Human Genome Assembly version
18 (hg18) which was downloaded from UCSC genome browser.
Methylation peaks, with a fold change less than 10 compared to
input, were filtered out for both MM and HD samples. Differential
methylation was determined by the presence or absence of
overlapping methylation peaks. Peaks that did not overlap with
any peaks found in the contrasting condition were considered to be
unique. The peaks were plotted using Circos (http://circos.ca/).
MicroRNA coordinates were obtained from NanoString technol-
ogies (Seattle, WA), and the peaks overlapping microRNA regions
were identified.
miRNA isolation and microRNA expression analysis
miRNAs were isolated from six MM cell lines with or without 5-
aza-CdR treatment (5 mM for 4 days) by miRNase mini kit
(Qiagen) [28]. Quality control was done using RNA6000 Nano
assay on the Aligent 2100 Bioanalyzer (Santa Clara, CA). miRNA
detection was conducted using the nCounter human miRNA
expression analysis system (Nanostring technologies, Seattle, WA)
and performed according to the manufacturer’s instructions.
Briefly, 100 ng of miRNA was used as input material, with 3 mlo f
the threefold-diluted sample. A specific DNA tag was ligated onto
the 39 end of each mature miRNA, providing exclusive
identification of each miRNA species in the sample. The tagging
was performed in a multiplexed ligation reaction utilizing reverse
complementary bridge oligonucleotides to dispose the ligation of
each miRNA to its designated tag. All hybridization reactions were
incubated at 64uC for 20 hours and then applied to the nCounter
Preparation Station for automated removal of excel probes and
immobilization of probe-transcript complexes on a streptavidin-
coated cartridge. Data collection was carried out in the nCounter
Digital Analyzer by counting individual fluorescent barcodes and
quantifying target miRNA molecules present in each sample. Data
normalization was performed by nSolver Analysis Software
according to the manufacturer’s instructions. Six internal positive
spike controls were used to account for minor differences in
hybridization and purification efficiencies, and six negative
controls were used for the consideration of background hybrid-
ization.
Bisulfate treatment and PCR conditions
Genomic DNA (gDNA) was isolated from MM cells with
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) as previously
described [23]. 500 ng of gDNA was modified by treatment with
sodium bisulfate using the EZ DNA Methylation-Gold Kit
(Zymo Research, Orange County, CA), which induces chemical
Epigenetics in Myeloma
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cytosines being protected from this conversion [29]. The
sequences of miRNA and its promoter were analyzed by using
miRBase and the University of California at Santa Cruz Human
Genome Browser (UCSC). CpG islands and specific primers for
MSP and bisulfite-sequencing PCR (BSP) were designed by
MethPrimer Tools (http://www.urogene.org/methprimer/) [30].
MSP analysis was performed with primers specific for either the
Figure 1. Methylation status of whole-genome sequencing data in MM and healthy donors. (A) Circular representation of DNA
methylation levels in whole genome regions for MM and healthy donors (HD). (B) Genome-wide distribution of methylation peaks by gene regions in
HD/MM only. (C) Methylation levels of regions around all known miRNAs in MM patients in decreasing order by peak intensity. Data was presented as
log2 values. (D) Venn diagram compared ChIP-chip and miRNA microarray data, as well as miRNAs being present with CpG island. Left, miRNAs
identified as high potential methylation with the definition of a difference $1.5-fold between MM and HD; Right: miRNAs up-regulated by more than
1.5-fold in at least two cell lines with 5-aza-CdR treatment; Bottom: miRNAs with CpG island. (E) Heatmap of the 24 overlay miRNAs in six MM cell lines
with or without 5-aza-CdR treatment. Red, high expression; blue, low expression.
doi:10.1371/journal.pone.0110973.g001
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quality and successful DNA modification, human genomic DNA,
with methylated CpG sites, was used as the positive control; H2O
was used as the negative control. Amplified bisulfate PCR
products were subcloned into the pGEM-T Easy vector (Promega,
Madison, WI). Eight independent clones for each sample were
selected and the T7 primers were used to sequence inserted
fragments. Primers used are shown in File S1.
Quantitative Real-time PCR
Quantitative Real-time PCR was performed as described
previously [28]. Briefly, total RNA or miRNA from cells was
isolated with RNeasy or miRNeasy Mini kit (QIAGEN). cDNA
was synthesized using the SuperScript cDNA synthesis kit
(Invitrogen) or High Capacity cDNA Reverse Transcription Kit
(Life Technologies, Grand Island, NY) and quantitative RT-PCR
(qRT-PCR) reactions were performed using SYBR MasterMix
(Qiagen) by StepOnePlus Real-Time PCR System (Applied
Biosystems, Foster city, CA) in triplicate. 18S or RNU6B was
used to normalize the miRNA and mRNA data, respectively.
Expression was calculated using the 2
2DDCt method. Primers used
are described in File S1.
miRNA transfection
MM.1S, RPMI 8226, IM9 and H929 cell lines were transfected
with hsa-miR-152, -10b-5p and -34c-3p mirVana miRNA or
negative control mimics (Life Technologies, Grand Island, NY) at
a final concentration of 50 nM, using Lipofectamine 2000
following manufacturer’s instructions. Efficiency of transfection
was validated by real-time PCR.
Cell proliferation assays
Cell proliferation was measured by the incorporation of [
3H]
thymidine uptake assay (Perkin Elmer, Boston, MA), as described
previously [22]. MM cells were incubated in 96-well plates
transfected with miR-152, -10b-5p and miR-34c-3p and negative
control mimics, respectively, following by being pulsed with [
3H]
thymidine (0.5 mCi/well) for at least 8 h of 48 h cultures. Cells
were harvested onto glass filters with an automatic cell harvester
(Cambridge Technology, Cambridge, MA), and counted using the
LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD).
All experiments were performed in four-well repeat.
Immunoblotting
Sodium dodecyl sulfate-polyacrylamidegel electrophoresis
(SDS-PAGE) and western blotting were performed as previously
described [23]. In brief, whole-cell lysates were separated using
10–12% gels and transferred to polyvinyldenefluoride (PVDF)
membranes (Bio-Rad Laboratories, Hercules, CA). The antibodies
used for immunoblotting included anti-PARP, -caspase 9, caspase
3 and a-tubulin (Cell Signaling Technology, Danvers, MA).
Figure 2. Identification and expression of miRNA candidates in MM. (A) Effect of 5-aza-CdR on the expression of miR-152, -10b-5p and miR-
34c-3p in six MM cell lines by real-time PCR. Experiments were performed in triplicate and RNU6B was used as the internal control. Data were shown
as means 6 SD.
*P,0.05 compared with cells without 5-aza-CdR. (B) Expression levels of miR-152 and miR-10b-5p in MM and healthy donor in
GSE16558.
doi:10.1371/journal.pone.0110973.g002
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miR-152 and miR-10b-5p expression was analyzed using
publicly available dataset where primary bone marrow selected
CD138+ cells were obtained from either MM patients or HDs
(GSE16558). Similarly, the expression levels of DNMT1, E2F3,
BTRC and MYCBP were analyzed using publicly available
datasets where primary bone marrow selected CD138+ cells
obtained from either MM patients or healthy individuals were
Figure 3. Methylation of miR-152, -10b-5p and miR-34c-3p in MM cells. (A) Schematic illustration of the percentage of C + G nucleotides
(CG%) and the density of CpG olinucleotides were shown for a region spanning 1000 bp upstream and 500 bp downstream of miR-152, miR-10b-5p
and miR-34c-3p, respectively. Specific primers for these CpG islands were designed (arrows) and used to amplify these DNA fragments in MM cell
lines. The CpG island was depicted, and each vertical bar illustrated a single CpG. (B) Representative MSP results of the three miRNAs methylation
inMM1S, RPMI 8266, OPM2, U266, IM9 and H929 cell lines. M: methylated primers; U: unmehtylated primers. PC: positive control. (C) Bisulfite
sequencing analysis showed relative methylation frequencies of miR-152, -10b-5p and miR-34c-3p in six MM cell lines. Eight single clones for each
sample were selected and T7 primers were used for sequencing. (D) Bisulfite sequencing analysis showed methylation frequencies of miR-152 and
miR-34c-3p in H929 and IM9, and miR-10b-5p in H929 and MM1S, treated with or without 59-aza-CdR (5 mM) for 4 days. Black and white circle
represented methylated and unmethylated CpG, respectively. (E) Representative sequencing results showed that the cytosine (C) residues of CpG
dinucleotides were converted into thymidine (T).
doi:10.1371/journal.pone.0110973.g003
Epigenetics in Myeloma
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e110973studied (GSE5900; GSE 2658) [31]. Gene Sets Enrichment
Analysis (GSEA) was performed by using gene sets publicly
available from the Broad Institute (Cambridge, MA; http://www.
broadinstitute.org/gsea/index.jsp), as previously reported [32,33].
Specifically, the following gene sets were used: TGCACTG, MIR-
148A, MIR-152, MIR-148B; ACAGGGT, MIR-10A, MIR-10B
and CACTGCC, MIR-34A, MIR-34C, MIR-449.
We used the easy-to-use graphical user interface of GSEA with
gene set permutation to derive significance, with signal-to-noise as
the distance metric and maximum expression to collapse probe
sets to genes.
Statistical analysis
miRNA expression data were normalized according to manu-
facturer’s instructions (Nanostring technologies, Seattle, WA). To
further define those miRNAs differentially expressed between
groups (with vs without 5-aza-CdR treatment), the expression
patterns of normalized data were analyzed and hierarchical
clustering was performed using dChip (http://www.hsph.harvard.
edu/cli/complab/dchip/) [34]. The enrichment analysis of
targeted mRNAs of miR-152, -10b-5p and miR-34c-3p in GEO
datasets was performed using GSEA, and considered significant
with false discovery rate (FDR) ,0.25, as previously reported (31).
Mann-Whitney U rank ranksum test with GraphPad software was
applied to describe the distribution of miRNAs and gene levels in
MM patients compared with HDs. Statistical tests were unpaired,
2-sided t-tests comparing two conditions. P values less than 0.05
were considered significant. Data were presented for the purpose
of figures as means and error bars.
Results
Global changes in DNA methylation occur in MM patients
We first interrogated genome-wide methylation patterns in
relapsed/refractory MM patients and HDs, and found a
significant increase in global methylation in relapsed MM
compared to HDs; circular representation of DNA methylation
levels per each chromosome in MM and healthy donor is
represented in Fig. 1A. The majority of methylation peaks were
located in the intronic and intragenic regions in MM samples.
Over half of the methylation peaks were identified within in intron
regions (51.9% in HD and 59.6% in MM), without significant
differences between HDs and MM. However, there were more
significant regions differentially methylated in the 39-UTR,
promoter-TSS, exon, 59-UTR, TTS and non-coding regions in
MM compared with HDs (Fig. 1B). Of note, an 8.5-fold increase
of non-coding regions was observed in MM compared to HDs.
This leads us to hypothesize that methylation of miRNAs can be
critical for the regulation of expression patterns of miRNAs in
MM. We, therefore, mapped probe values of all known miRNAs
to determine whether miRNA-related regions were differentially
methylated in MM. As shown in Fig. 1C, there was a significant
increase in the number of hypermethylated miRNAs compared to
the number of miRNAs with hypomethylation. Specifically, 127
miRNAs were identified as highly methylated miRNAs with $1.5-
fold change increase in MM compared to HDs (log2) (File S2).
These findings suggested that miRNAs are highly methylated in
MM and may therefore explain in part the global decrease in
miRNA expression in these tumor cells.
To further examine the role of methylation in miRNA
regulation in tumor cells, MM cell lines (MM.1S, RPMI 8266,
OPM2, U266, IM9 and H929) were treated with the DNA
methyltransferase inhibitor 5-aza-CdR and the global level of
miRNAs was examined. Hierarchical clustering analysis of cell
lines was performed and demonstrated up-regulation of miRNAs
in response to treatment with 5-aza-CdR treatment with a.1.5-
fold difference. Overall, 241 miRNAs were up-regulated in at least
two cell lines with 5-aza-CdR (File S3), 77 miRNAs were up-
regulated in three cell lines and 7 miRNAs were up-regulated in
four cell lines treated.
To further identify the most critically regulated miRNAs, we
identified 48 miRNAs that were present in the methylation sites of
MM patient samples and were also up-regulated in response to 5-
aza-CdR treatment in MM cell lines (Fig. 1D). Among them, 4
miRNAs, miR-3605-5p, -4461, -4516 and miR-4531, were not
present in UCSC and were excluded; 44 miRNAs remained. We
then assessed the status of CpG islands for these 44 miRNAs and
found that only 24 miRNAs were present in one or more CpG
island upstream regulatory sequences (Fig. 1D&E).
Identification and expression analysis of miRNA
candidates in MM
Among the 24 miRNAs, miR-152 was the most frequently up-
regulated miRNA with 5-aza-CdR treatment (in all six cell lines).
In addition, miR-10b-5p was up-regulated by more than 2.0-fold
in at least three cell lines following treatment with 59-aza-CdR.
Therefore, we further examined the functional significance of
miR-152 and miR-10b-5p in parallel with miR-34c-3p, which was
also included in the 24 miRNAs and has been reported to be
methylated in MM [35].
Further validation of the re-expression of these miRNAs was
performed by real-time PCR and indeed confirmed that miR-152,
-10b-5p and miR-34c-3p were significantly increased following
exposure to 5-aza-CdR (Fig. 2A). Of note, all of the regions
around these three miRNAs were highly methylated in MM
patients as previously shown in Fig. 1C. We next analyzed the
expression levels of these miRNAs in MM using GSE16558, and
found that both miR-152 and miR-10b-5p were significantly
down-regulated in MM patients compared to HD (Fig. 2B).
Table 1. Methylation frequency of miR-152, -10b-5p and miR-34c-3p in MM cell lines.
Methylation frequency (%)
MM1S RPMI 8266 OPM2 U266 IM9 H929
miR-152 8.0 82.4 63.6 6.3 84.1 77.3
miR-10b-5p 77.9 57.7 26.9 82.7 45.2 63.5
miR-34c-3p 1.2 9.2 66.2 58.5 74.3 59.5
doi:10.1371/journal.pone.0110973.t001
Epigenetics in Myeloma
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miR-34c-3p in MM cells
miR-152, -10b-5p and miR-34c-3p present with 2, 3 and 3
distinct CpG islands in their upstream chromosomal regions,
respectively (1000 bp upstream and 500 bp upstream) as shown in
Fig. 3A. We further examined the methylation status of these
miRNAs using MSP analysis and showed that the miR-152
upstream promoter region was methylated in RPMI 8266, OPM2,
IM9 and H929 cells; while partial/no methylation was detected in
MM.1S and U266 cells. Moreover, miR-10b-5p methylation was
observed in all MM cell lines tested. Complete methylation of
miR-34c-3p was observed in IM9 and H929; while partial
methylation was found in OPM2 and U266; in contrast with
MM.1S and RPMI 8266 that were unmethylated (Fig. 3B). To
demonstrate the frequency of CpG island methylation in these
Figure 4. miR-152, -10b-5p and miR-34c-3p modulated proliferation and apoptosis of MM cells. Since the three miRNAs have different
methylation frequencies and expression levels in MM cell lines, H929 cells were transfected with miR-152, -10b-5p and -34c-3p mirVana miRNA
respectively; IM9 cells were transfected with miR-152 and -34c-3p mirVana miRNA respectively; MM1S cells were used to overexpress miR-10b-5p. All
of the cells transfected with negative control mimics used as control cells. (A) The indicated transfected cells were cultured in presence or absence
with primary BMSCs for 72 hours, following by [H]
3 thymidine uptake assay. NC-transfected cells in absence with BMSCs were defined as 1.0 and
regarded as the control group.
*P,0.05. (B) MM cells (NC-, miR-152-, -10b-5p-, or miR-34c-3p-transfected) were harvested at 48 or 72 hours after
transfection. Whole cell lysates were subjected to western blotting using anti-PARP, -Caspase 9, -Caspase 3 and -a-tubulin antibodies.
doi:10.1371/journal.pone.0110973.g004
Epigenetics in Myeloma
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clones (Fig. 3C). Detailed analysis has been provided in Table 1.
These results support that miR-152, miR-10b-5p and miR-34c-3p
hypermethylation frequently occurs in MM cells. In addition, the
results of MSP and BSP suggest that the methylation of miRNAs is
cell-type specific.
To determine whether 5-aza-CdR may modulate miRNA
methylation status in MM cells, bisulfite sequencing was further
performed in H929, IM9 and MM1S cells for specific miRNAs
respectively, which was based on their different methylation
frequencies in each cell line. As shown in Fig. 3D, the methylation
frequencies of miR-152 decreased from 77.3% to 20.5% in H929,
and 84.1% to 16.3% in IM9 cells after 5-aza-CdR treatment.
Similar results were found for miR-10b-5p in H929 (63.46% to
2.02%) and MM1S (77.88% to 1.25%) cells, as well as for miR-
34c-3p in H929 (59.46% to 23.65%) and IM9 (74.32% to
Figure 5. Effect of miR-152 and miR-10b-5p on the expression of putative targets. (A) GSEA established that predicated targets of miR-152
and miR-10b-5p was positively correlated with MM, and negatively correlated with HD. NES: normalized enrichment score; FDR: false discovery rate.
(B) The expression of predicted targets of miR-152 (DNMT1 and E2F3) and miR-10b-5p (E2F3, BTRC and MYCBP) in miR-152-, -10b-5p- or NC-
transfected MM cells by real-time PCR with normalization to the reference 18S expression.
*P,0.05 compared with NC-transfected cells. (C) The
expression of DNMT1, E2F3, BTRC and MYCBP in healthy donor and MM (GSE5900 and GSE2658).
doi:10.1371/journal.pone.0110973.g005
Epigenetics in Myeloma
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cytosines (C) to uracil (T) are shown in Fig. 3E. Taken together,
these findings suggest that the CpG-rich promoter regions of miR-
152, -10b-5p and miR-34c-3p are hypermethylated and present
with low expression in MM cells.
MiR-152, -10b-5p and miR-34c-3p act as tumor
suppressors in MM
We next examined the potential functional relevance of miR-
152, -10b-5p and -34c-3p in MM. We therefore, examined the
role of these 3 miRNAs in the growth of tumor cells alone or in the
presence of bone marrow stromal cells (BMSCs) using gain of
function studies. Efficiency of transfection with miR-152, -10b-5p
and miR-34c-3p was first demonstrated using real-time PCR
(Figure S1). There was a significant inhibition of proliferation of
MM cells in response to re-expression of miR-152, -10b-5p and
-34c-3p in MM cells, even in the presence of BMSCs, indicating
that these miRNAs are critical for the growth and proliferation of
MM cells even in the presence of the bone marrow microenvi-
ronment (Figure 4A, P,0.05). The effects of these miRNAs in
modulating MM cell apoptosis was also investigated; re-expression
of miR-152, -10b-5p and miR-34c-3p mimics induced cleavage of
PARP- and caspase-9 and -3, compared to normal control-
transfected cells (Fig. 4B). These findings suggest that miR-152,
-10b-5p and miR-34c-3p may act as putative tumor suppressors in
MM by inhibiting cell proliferation and inducing apoptosis.
MiR-152 and miR-10b-5p mediate the activation of
oncogenic target genes
Given that miRNAs inhibit mRNA expression, we hypothesized
that the predicted target genes of these specific miRNAs are highly
expressed in CD138
+ bone marrow-derived MM cells. We
therefore screened publically available mRNA datasets
(GSE5900; GSE2658) and found that MM patients present with
a significant enrichment of miR-152- and miR-10b-target genes,
as shown by GSEA (FDR,0.25; Fig. 5A), whereas no significant
differences were observed for miR-34c-predicted targeted genes.
We next focused on the predicted genes of miR-152- and miR-
10b-5p. DNA-methyltransferase 1 (DNMT1), a predicted target of
miR-152; beta-transducin repeat containing E3 ubiquitin protein
ligase (BTRC) and Myc binding protein (MYCBP), predicted
targets of miR-10b-5p and E2F transcription factor 3 (E2F3),
predicted target of both miR-152 and miR-10b-5p were examined
in MM cells (Figure S2). Enhanced expression of miR-152
induced a significant reduction of DNMT1 and E2F3 expression.
In addition, E2F3, BTRC and MYCBP were significantly
increased after miR-10b-5p mimic transfection (Fig. 5B). More-
over, we confirmed that the expression of these genes is
significantly up-regulated in MM patients compared to healthy
donors using GSE5900 and GSE2658 as shown in Fig. 5C. These
results suggest that methylation of miR-152 and miR-10b-5p
enhances MM progression through increased expression of specific
oncogenes, such as DNMT1, BTRC, MYCBP and E2F3.
Discussion
Aberrant promoter hypermethylation has been described in
tumors for specific gene clusters in MM [4,35]. In addition, recent
studies have shown that MM is characterized by highly variable
DNA methylation patterns that exceed the methylation variability
seen in several solid cancers, with focal hypermethylation changes
in clinically aggressive subtypes, such as plasma cell leukemia and
patients with translocation t(4;14), suggesting that methylation
changes can affect disease biology [36]. Moreover, Kaiser et al
[16] identified epigenetically repressed tumor suppressor genes
that were associated with prognostic relevance in myeloma. In our
study, we found that the majority of methylation peaks were
located in the intronic and intragenic regions in MM samples.
Therefore, we investigated the effect of methylation on miRNA
regulation in MM.
miRNAs act as tumor suppressors or oncogenic activators in
many cancers, however, the majority of cancers present with
global suppression of miRNAs including MM [6,7,10,11,36–38].
To date, the mechanism of global miRNA suppression in cancers,
and specifically in MM, has not been investigated. In this study, we
showed that hypermethylation occurred in regions of miRNAs in
MM, compared to HDs indicating that miRNAs are highly
methylated in MM, which could explain the global decrease of
miRNA expression in MM cells. These studies were confirmed in
MM cell lines using bisulfite sequencing and MSP in the presence
or absence of the demethylating agent 5-aza-CdR.
Our studies describe the presence of hypermethylation-depen-
dent inhibition of miR-152, -10b-5p and -34c-3p, which were
shown to exert a putative tumor suppressive role in MM. We
identified these miRNAs though global methylation studies in
patient samples as well as providing functional validation in MM
cell lines with bisulfite sequencing and MSP in the presence or
absence of 5-aza-CdR. These findings were corroborated by the
demonstration that the same miRNAs were present at lower level
in MM patients compared to healthy individuals, together with
enrichment of miR-152-, -10b-5p, and -34c-3p-predicted targets
as shown at the mRNA level in primary MM cells. Demethylation
or re-expression of these specific miRNAs led to induction of
apoptosis and inhibition of proliferation as well as down-regulation
of putative oncogene targets of these miRNAs.
MiR-10b may exert a bifunctional role, as shown by its activity
as oncogene or tumor suppressor depending on the specific tumor
type. For instance, it may positively regulate cell invasion and
metastasis in breast cancer through Twist modulation [39,40]. In
pancreatic cancer, miR-10b has been reported to enhance cell
invasion by suppressing TIP30 expression and promoting EGF-
and TGF-b-mediated pathways and it can be also considered as a
novel diagnostic biomarker [41]. In contrast, miR-10b has been
shown to play a tumor suppressive role in gastric cancer and
endometrial serous adenocarcinomas [42,43]. In our studies, we
found that miR-10b-5p (previous ID: miR-10b) was down-
regulated via promoter methylation, resulting in inhibition of
MM cell proliferation. Importantly, methylation of miR-10b-5p
occurred in the MM patient samples based on a global
methylation analysis [16]. These findings suggest that miR-10b-
5p is regulated through different mechanisms, such as transcrip-
tion regulation and promoter methylation, thereby presenting
different expression profiles and functions in different types of
tumors.
Aberrant methylation of miR-152 has been reported in both
solid tumors and hematological malignancies. Previous studies
show that miR-152 is methylated and inhibits cell growth and
proliferation in breast and endometrial cancer [44,45]. In
addition, methylation of miR-152 contributes to its down-
regulation in hepatitis B virus-related hepatocellular carcinoma
(HCC) [46]. miR-152, among others, is down-regulated in t(4;11)
positive ALL as a consequence of CpG methylation [47].
Moreover, an association between miR-152 expression and lower
survival in patients with MM has been previously demonstrated
[48]. Interestingly, it has been reported miR-152 is down-
regulated in hyperdiploid MM compared with non-hyperdiploid
disease, leading to the up-regulation of several oncogenes [49].
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established target genes, we selected several putative oncogenes to
study, such as DNMT1, E2F3, BTRC and MYCBP. Among
them, DNMT1 is a major enzyme responsible for maintenance of
DNA methylation patternspatter. Its aberrant expression is the
dominant mechanism for the genome instability, which associates
with tumorigenesis and cancer development [50]. E2F3 functions
as a transcription factor which is involved in the regulation of cell
proliferation [51]. In fact, it has been observed that DNMT1 and
E2F3 are candidate targets of miR-152 in HCC, endometrial and
breast cancer [44–46]; BTRC has been shown to ubiquitinate
phosphorylated NFKBIA, targeting it for degradation and thus
activating NF-kB [52]. MYCBP is able to enhance c-Myc’sMyc
ability to activate E box-dependent transcription [53]. The
activation of both NF-kB and c-Myc partly contributes to the
progression of MM. In our study, we found that down-regulation
of miR-152 and miR-10b-5p is supported by over-expression of
DNMT1, E2F3, BTRC and MYCBP in MM patients. More
importantly, ectopic expression of miR-152 or miR-10b-5p
significantly down-regulated the mRNA level of these genes.
Hence, we conclude that MM cell proliferation may be mediated,
at least in part, through methylation and down-regulation of miR-
152- and miR-10b-5p which in turn lead to activation of DNMT1,
E2F3, BTRC and MYCBP.
In conclusion, our studies indicate that global miRNA
suppression in MM may be due to hypermethylation of non-
coding regions in the MM genome. More specifically, miR-152,
-10b-5p and miR-34c-3p are epigenetically silenced in MM
through CpG island methylation; and act as potential tumor
suppressor miRNAs in this disease. Re-expression of these
miRNAs led to suppression of oncogenes and the inhibition of
proliferation and induction of apoptosis in MM cells. These
findings establish an important mechanism of miRNA deregula-
tion in MM. Specifically, we suggest that miR-152, -10b-5p and
miR-34c-3p promoter methylation may represent useful molecular
biomarkers for assessing the risk of MM development. Most
importantly, our study might provide a mechanistic and molecular
basis for a new therapeutic use for pharmacological compounds
with DNA demethylating activity in the treatment of MM patients.
Supporting Information
Figure S1 Validation of miRNA expression by real-time
PCR. The indicted cells were transfected with miR-152, -10b-5p,
-34c-3p or negative control (NC) respectively. miRNA levels were
detected by real-time PCR, and normalized to RNU6B control.
Data were shown as means 6 SD.
*P,0.05 compared with NC-
transfected cells.
(TIF)
Figure S2 Binding of miR-152 or miR-10b-5p to the
indicated target mRNAs at different sites. Complementary
sites between miR-152 and DNMT1 and E2F3, and between
miR-10b-5p and E2F3, BTRC and MYCBP according to
Targetscan 6.2.
(TIF)
File S1 List of primer sequences and PCR products.
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File S2 MM patients present with higher miRNA
methylation as compared to healthy individuals.
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File S3 5-aza-CdR-dependent modulation of miRNAs in
MM cell lines.
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